\-\ Texto\\:\\ \ \(0\)\
\-\ within\\ normal\\ limits\\.\ \(131\)\
\-\ non\\-contrast\\ axial\\ ct\\ image\\ demonstrates\\ a\\ well\\-circumscribed\\ smoothly\\ marginated\\,\\ heterogeneous\\ 3\\.5\\ x\\ 3\\.2\\ cm\\ mass\\ arising\\ from\\ the\\ left\\ adrenal\\ gland\\.\\ \\ there\\ are\\ areas\\ within\\ the\\ mass\\ that\\ are\\ low\\ density\\ and\\ measure\\ 5\\ hu\\.\\ \\ \\ 50\\ seconds\\ postcontrast\\ axial\\ ct\\ image\\ demonstrates\\ the\\ lesion\\ to\\ enhance\\ heterogeneously\\,\\ with\\ areas\\ within\\ the\\ mass\\ measuring\\ 113\\ hu\\.\\ \\ 15\\-minute\\ delay\\ postcontrast\\ axial\\ ct\\ image\\ demonstrates\\ the\\ lesion\\ to\\ enhance\\ heterogeneously\\,\\ with\\ areas\\ within\\ the\\ mass\\ measuring\\ 35\\ hu\\.\\ \\ the\\ percentage\\ enhancement\\ washout\\ was\\ determined\\ to\\ be\\ 72\\%\\ consistent\\ with\\ a\\ benign\\ adrenal\\ adenoma\\.\ \(0\)\
\-\ benign\\ adrenal\\ adenoma\ \(1\)\
\-\ metastases\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\(lung\\,\\ breast\\,\\ melanoma\\,\\ gastrointestinal\\,\\ and\\ renal\\ cell\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ carcinoma\\ \\)\ \(0\)\
\-\ adrenal\\ myelolipoma\ \(1\)\
\-\ benign\\ nonfunctional\\ adrenal\\ adenoma\ \(0\)\
\-\ hyperfunctioning\\ adrenal\\ neoplasms\\ with\\ associated\\ endocrine\ \(0\)\
\-\ \\ \\ \\ \\ \\ syndromes\\:\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\(cushing\\â\\€\\™s\\ syndrome\\,\\ conn\\â\\€\\™s\\ syndrome\\,\\ adrenogenital\\ syndrome\\ in\ \(0\)\
\-\ \\ \\ \\ \\ \\ newborns\\ and\\ infants\\.\\)\ \(1\)\
\-\ \\ \\ \\ \\ \\ pheochromocytoma\ \(0\)\
\-\ infectious\\ etiologies\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ tuberculosis\ \(0\)\
\-\ \\ \\ \\ \\ \\ histoplasmosis\\ \ \(0\)\
\-\ primary\\ adrenal\\ carcinoma\ \(0\)\
\-\ 53\\ yo\\ asymptomatic\\ female\\ with\\ known\\ adrenal\\ mass\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adrenal\\:\\ 0\\.5583886226037141\ \(0\)\
\-\ hu\\:\\ 0\\.25168114647443596\ \(0\)\
\-\ postcontrast\\:\\ 0\\.18610280892094588\ \(0\)\
\-\ adenoma\\:\\ 0\\.180253567008705\ \(0\)\
\-\ heterogeneously\\:\\ 0\\.15652878786578522\ \(0\)\
\-\ benign\\:\\ 0\\.1553112696283013\ \(0\)\
\-\ areas\\:\\ 0\\.1535020981904808\ \(0\)\
\-\ image\\:\\ 0\\.14459537746851742\ \(0\)\
\-\ mass\\:\\ 0\\.14393640908282196\ \(0\)\
\-\ within\\:\\ 0\\.13884252268097466\ \(0\)\
\-\ syndrome\\:\\ 0\\.13630326715734092\ \(0\)\
\-\ enhance\\:\\ 0\\.13492202621283192\ \(0\)\
\-\ axial\\:\\ 0\\.13059998431035166\ \(0\)\
\-\ adrenogenital\\:\\ 0\\.12052447136745578\ \(0\)\
\-\ measuring\\:\\ 0\\.11660664827484336\ \(0\)\
\-\ conn\\:\\ 0\\.11516756672732635\ \(0\)\
\-\ demonstrates\\:\\ 0\\.11358713162857262\ \(0\)\
\-\ nonfunctional\\:\\ 0\\.1113667823984615\ \(0\)\
\-\ hyperfunctioning\\:\\ 0\\.1113667823984615\ \(0\)\
\-\ the\\:\\ 0\\.10526583988437714\ \(0\)\
\-\ newborns\\:\\ 0\\.10220909342946723\ \(0\)\
\-\ 113\\:\\ 0\\.09800176156346525\ \(0\)\
\-\ cushing\\:\\ 0\\.09685218878933778\ \(0\)\
\-\ seconds\\:\\ 0\\.09305140446047294\ \(0\)\
\-\ myelolipoma\\:\\ 0\\.09149528414920834\ \(0\)\
\-\ percentage\\:\\ 0\\.09078096140550043\ \(0\)\
\-\ carcinoma\\:\\ 0\\.09015944632805654\ \(0\)\
\-\ washout\\:\\ 0\\.0901032870971136\ \(0\)\
\-\ smoothly\\:\\ 0\\.0876944998203435\ \(0\)\
\-\ measure\\:\\ 0\\.08715516973375426\ \(0\)\
\-\ ct\\:\\ 0\\.08607608172166832\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.08519428136578643\ \(0\)\
\-\ histoplasmosis\\:\\ 0\\.08389371549147864\ \(0\)\
\-\ endocrine\\:\\ 0\\.08197560671553969\ \(0\)\
\-\ marginated\\:\\ 0\\.0793894778168547\ \(0\)\
\-\ infants\\:\\ 0\\.0785368108513492\ \(0\)\
\-\ syndromes\\:\\ 0\\.0774793064112125\ \(0\)\
\-\ etiologies\\:\\ 0\\.07558869348798986\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.07432947898534724\ \(0\)\
\-\ with\\:\\ 0\\.0737866966549382\ \(0\)\
\-\ 72\\:\\ 0\\.07264057612463051\ \(0\)\
\-\ lesion\\:\\ 0\\.07226297294456435\ \(0\)\
\-\ determined\\:\\ 0\\.07178790915912502\ \(0\)\
\-\ 53\\:\\ 0\\.0705286946564824\ \(0\)\
\-\ melanoma\\:\\ 0\\.07037940772954157\ \(0\)\
\-\ neoplasms\\:\\ 0\\.07023178884786042\ \(0\)\
\-\ delay\\:\\ 0\\.06910670496389833\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.06632136279048043\ \(0\)\
\-\ gland\\:\\ 0\\.061221718760547286\ \(0\)\
\-\ metastases\\:\\ 0\\.06092811217842805\ \(0\)\
\-\ infectious\\:\\ 0\\.06064088885646998\ \(0\)\
\-\ 35\\:\\ 0\\.06042949630730016\ \(0\)\
\-\ arising\\:\\ 0\\.0598817804683116\ \(0\)\
\-\ limits\\:\\ 0\\.05955064151862859\ \(0\)\
\-\ are\\:\\ 0\\.05719490904265929\ \(0\)\
\-\ to\\:\\ 0\\.056523038264817624\ \(0\)\
\-\ breast\\:\\ 0\\.05472761769610556\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.05454724967343032\ \(0\)\
\-\ 50\\:\\ 0\\.05263277266160317\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.05130680537853743\ \(0\)\
\-\ density\\:\\ 0\\.04997451859472593\ \(0\)\
\-\ known\\:\\ 0\\.04879330088939384\ \(0\)\
\-\ yo\\:\\ 0\\.04708355381852398\ \(0\)\
\-\ renal\\:\\ 0\\.046931692922851785\ \(0\)\
\-\ and\\:\\ 0\\.04671954247852653\ \(0\)\
\-\ primary\\:\\ 0\\.04634112522400043\ \(0\)\
\-\ lung\\:\\ 0\\.0458451835260345\ \(0\)\
\-\ enhancement\\:\\ 0\\.043378576671372744\ \(0\)\
\-\ cm\\:\\ 0\\.04328276948965913\ \(0\)\
\-\ low\\:\\ 0\\.043244640307461\ \(0\)\
\-\ cell\\:\\ 0\\.04311204813045337\ \(0\)\
\-\ consistent\\:\\ 0\\.04086443959603389\ \(0\)\
\-\ associated\\:\\ 0\\.03972281852389883\ \(0\)\
\-\ female\\:\\ 0\\.03636691637760748\ \(0\)\
\-\ that\\:\\ 0\\.03270542884651393\ \(0\)\
\-\ normal\\:\\ 0\\.030770878467738415\ \(0\)\
\-\ be\\:\\ 0\\.0305724228216984\ \(0\)\
\-\ there\\:\\ 0\\.029987357627392335\ \(0\)\
\-\ from\\:\\ 0\\.02993164114012968\ \(0\)\
\-\ was\\:\\ 0\\.026265324291448133\ \(0\)\
\-\ left\\:\\ 0\\.025708523490160708\ \(0\)\
\-\ in\\:\\ 0\\.018748277329180475\ \(0\)\
